Related Experiment Video

Updated: May 19, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Small-cell lung cancer treatment: where is the target?

James Chih-Hsin Yang

    Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
    |August 17, 2012
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles
    08:03

    Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles

    Published on: December 1, 2016

    Related Experiment Videos

    Last Updated: May 19, 2026

    Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
    04:04

    Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

    Published on: February 12, 2017

    Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles
    08:03

    Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles

    Published on: December 1, 2016

    Related Concept Videos

    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against specific...
    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against specific...

    Articles linked to this work by shared authors, journal, and citation graph.

    Selpercatinib in Early-Stage RET Fusion-Positive Non-Small-Cell Lung Cancer.

    The New England journal of medicine·2026

    TROPION-Lung14 study protocol: a phase III study of osimertinib in combination with datopotamab deruxtecan versus osimertinib alone as first-line treatment for patients with EGFR-mutated locally advanced or metastatic non-small cell lung cancer.

    Therapeutic advances in medical oncology·2026

    Long-Term Impact of First-Line Amivantamab Plus Lazertinib Versus Osimertinib on Mechanisms of Acquired Resistance in MARIPOSA: A Brief Report.

    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026

    Consensus Statement on ctDNA Minimal Residual Disease Testing in Early Stage NSCLC: A Delphi Study by the Asian Thoracic Oncology Research Group.

    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026

    Time to achieve response and depth of maximal tumor response as potential surrogates for overall survival in advanced non-small cell lung cancer.

    Future oncology (London, England)·2026

    Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody.

    Clinical cancer research : an official journal of the American Association for Cancer Research·2026

    Sutetinib for Patients with Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase IIb Trial.

    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026

    Prognostic Significance of Spread Through Airspaces (STAS) in Stage Ia/bN0 Non-small Cell Lung Cancer - An Evaluation in the JCOG0802/WJOG4607L Clinical Trial Patients.

    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026

    Clinical Responses to Tarlatamab Among Patients with Pulmonary Carcinoid.

    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026

    Tumor mutational burden as a predictor of immune-related adverse events in patients with advanced non-small cell lung cancer receiving immune checkpoint inhibitors: a Brief Report.

    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026

    Lung Cancer Patient Advocacy Progress and New Challenges Since 2006.

    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026

    Comprehensive Patient Reported Outcomes (PROs) from NRG Oncology/Alliance LU005: A Randomized Trial Of Chemoradiation +/- Atezolizumab In Limited-Stage Small Cell Lung Cancer.

    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026

    Targeting CKIP-1 for Disease Therapy: Cellular Functions, Molecular Networks, and Clinical Potential.

    Cell proliferation·2026

    YTHDC1 Orchestrates Glucose and Glutamate Rewiring to Overcome Lethal Metabolic Stress in Triple-Negative Breast Cancer.

    Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026

    Natural Product Toosendanin Suppresses the Malignant Development of Skin Melanoma by Targeting BNC2 for Degradation.

    Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026

    An Immune-Activated Co-culture Model of Patient-Derived Gastric Cancer Organoids and Peripheral Blood Mononuclear Cells for Personalized Chemotherapy Screening.

    Acta biomaterialia·2026

    Cardio-renal protection of MRAs in kidney-transplanted diabetic patients.

    Pharmacological research·2026

    Substrate-Derived Peptides for Selective Covalent Inhibition of Protein Tyrosine Kinases.

    ACS chemical biology·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us